Constipation med linked to 46 B. cepacia cases in US recalled by PharmaTech

By Gareth Macdonald

- Last updated on GMT

iStock/jarun011
iStock/jarun011

Related tags Food and drug administration Medicine

A constipation medication made by PharmaTech LLC has been recalled after being linked to an outbreak of the bacteria B. cepacia in five US states.

The product in question - Diocto Liquid (NDC 0536-0590-85) – has been linked to 46​ cases of B. cepacia ​according to the US Centers for Disease Control and Prevention (CDC), which advised doctors not to use it.

[The] CDC continues to recommend that clinicians not use any liquid docusate product as a stool softener or for any other medical purpose. This recommendation is now expanded to all patient populations.

The organisation added that: “If an oral liquid docusate stool softener is medically necessary, alternative medicines should be used​.”

Recall

Florida-based contract manufacturing organisation (CMO) PharmaTech makes the product for Livonia, Michigan-based Rugby Laboratories. Details​ of the recall were posted on the US Food and Drug Administration (FDA) website on July 15. 

The firm said: "All lots with NDC 0536-0590-85 are included in the recall​" adding that it "learned of the potential issue through the receipt of two isolated complaints regarding this product.

PharmaTech's manufacturing facility is in Davie, Florida.

In March​, the firm announced the facility had passed an FDA inspection and was found to be "compliant with the principles and guidelines of Current Good Manufacturing Practices (cGMP), and no Form 483 observations were issued​."

PharmaTech did not respond to a request for comment.

Wider recall?

The FDA also said it has received several adverse event reports of B. cepacia infections in patients who treated with docusate products manufactured by companies other than PharmaTech. The Agency did not provide additional information.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars